Page last updated: 2024-11-09

diaminomaleonitrile, (z)-isomer

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

diaminomaleonitrile: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2723951
CHEMBL ID1701646
SCHEMBL ID170
MeSH IDM0314704

Synonyms (54)

Synonym
(z)-2,3-diamino-but-2-enedinitrile
AKOS015831345
2-butenedinitrile,3-diamino-, (z)-
hydrogen cyanide tetramer
maleonitrile, diamino-
2,3-diaminomaleonitrile
nsc266758
diaminomaleonitrile
1187-42-4
nsc-266758
NCGC00091234-01
2-butenedinitrile, 2,3-diamino-, (z)-
ccris 921
nsc 266758
einecs 214-697-6
2-butenedinitrile, 2,3-diamino-, (2z)-
inchi=1/c4h4n4/c5-1-3(7)4(8)2-6/h7-8h2/b4-3
diaminomaleonitrile, 98%
(2z)-2,3-diaminobut-2-enedinitrile
smr001370899
MLS002415726
D1335
1,2-diamino-1,2-dicyanoethylene
(z)-2,3-diaminobut-2-enedinitrile
A804086
NCGC00091234-02
2,3-dicyanoethenediamine
2-butenedinitrile, 2,3-diamino-
butenedinitrile, diamino-
HMS3039E16
e8c63n8twr ,
unii-e8c63n8twr
dtxcid004923
dtxsid0024923 ,
tox21_200991
cas-1187-42-4
damn
NCGC00258544-01
(2z)-2,3-diamino-2-butenedinitrile
BBL027361
SCHEMBL170
Q-200949
CHEMBL1701646
STR01749
(2z)-diaminobut-2-enedinitrile
(2z)-2,3-diamino-2-butenedinitrile #
F0001-0301
diaminomaleonitril
Q21099121
AMY11106
STL185612
P19757
2,3-diamino-2-butenedinitrile, (2z)-
n-(2-hydroxyethyl)-n-[3-(4-nitrophenyl)]propylamine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency31.62280.031637.5844354.8130AID743255
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency3.16230.707912.194339.8107AID720542
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency43.20450.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency26.50270.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency42.35220.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency67.44000.003041.611522,387.1992AID1159552; AID1159553; AID1159555
farnesoid X nuclear receptorHomo sapiens (human)Potency44.66840.375827.485161.6524AID588527
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency50.11870.001024.504861.6448AID588535
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.05980.023723.228263.5986AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency62.95200.000723.06741,258.9301AID743085; AID743122
Histone H2A.xCricetulus griseus (Chinese hamster)Potency71.06330.039147.5451146.8240AID1224845; AID1224896
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency32.64270.00419.984825.9290AID504444
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency5.62340.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency5.62340.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency5.62340.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency0.20600.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (18.18)18.7374
1990's1 (3.03)18.2507
2000's4 (12.12)29.6817
2010's14 (42.42)24.3611
2020's8 (24.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.78 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index5.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]